Business Context and Reporting Period
Pliant Therapeutics, Inc. (PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics. This Form 10-K covers the fiscal year ended December 31, 2025. The company's lead product candidate, PLN-101095, is an oral, small molecule dual inhibitor of αvβ8 and αvβ1 integrins in development for solid tumors resistant to immune checkpoint inhibitors. In 2025, the company discontinued the development of its former lead candidate, bexotegrast, for idiopathic pulmonary fibrosis (IPF) following the termination of the Phase 2b BEACON-IPF trial.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(149.3) million | $(210.3) million |
| Operating Expenses | $(156.4) million | $(228.4) million |
| Research & Development (R&D) | $(109.2) million | $(169.3) million |
| General & Administrative (G&A) | $(47.2) million | $(59.1) million |
| Cash, Cash Equivalents, and Short-Term Investments | $192.4 million | $355.7 million |
| Accumulated Deficit | $(859.4) million | $(710.1) million |
| Debt | $0 (Extinguished Oct 2025) | $30.2 million |
Note: The company reported no revenue for either period. Interest and other income, net, was $11.4 million in 2025 compared to $21.1 million in 2024.
Material Changes vs. Prior Period
- Cost Reductions: Total operating expenses decreased by 31.5% to $156.4 million, driven primarily by the discontinuation of the bexotegrast IPF program and workforce restructuring. R&D expenses fell 35.5% ($60.2 million decrease), with a $44.0 million reduction specifically attributed to the termination of the BEACON-IPF trial.
- Debt Extinguishment: In October 2025, the company voluntarily prepaid its Amended Loan Agreement with Oxford Finance LLC in full for $32.4 million. This resulted in a one-time loss on extinguishment of debt of $1.8 million but eliminated all outstanding debt obligations.
- Restructuring: The company executed two restructuring plans in 2025, reducing the workforce by approximately 45% in May and initiating further reductions in December. Total restructuring costs were $6.3 million ($3.8 million in May and $2.5 million in December).
- Cash Position: Cash and short-term investments declined from $355.7 million in 2024 to $192.4 million in 2025, reflecting operating cash burn and the debt prepayment.
Guidance, Outlook, and Risks
Outlook and Strategy: Management expects to continue incurring net losses for the foreseeable future. The company is accelerating the development of PLN-101095, having initiated a Phase 1b indication expansion trial in 2026 focusing on non-small cell lung cancer (NSCLC) and other tumor types. Management believes current capital resources are sufficient to fund operations for the next 12 months and beyond, though additional financing will be required to complete clinical development and commercialization.
Key Risks and Contingencies:
- Clinical Development Risk: The business is highly dependent on the success of PLN-101095. Failure in future clinical trials or inability to obtain regulatory approval would materially harm the company.
- Liquidity Risk: The company requires substantial additional capital. If funding is not available on acceptable terms, the company may be forced to delay or eliminate research programs.
- Third-Party Reliance: The company relies on third-party contract manufacturers (including vendors in China) and CROs for clinical trials and manufacturing. Supply chain disruptions or vendor failures could delay development.
- Regulatory and Pricing: Changes in healthcare legislation, such as the Inflation Reduction Act (IRA) and new executive orders on drug pricing, may impact future reimbursement and pricing strategies.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $192.4 million cash balance against the accelerated burn rate of the Phase 1b trial and ongoing operational costs.
- PLN-101095 Data: Review the detailed Phase 1 data presented at the AACR Annual Meeting 2026 to validate the efficacy signals (complete and partial responses) and the IFN-γ biomarker correlation.
- Debt Status: Confirm that the $32.4 million debt prepayment has fully discharged all covenants and obligations with Oxford Finance LLC.
- Restructuring Impact: Assess whether the 45% workforce reduction has stabilized operating expenses or if further cost-cutting measures (e.g., lease subletting) are imminent.
- Manufacturing Supply Chain: Evaluate the risks associated with reliance on single-source vendors and foreign jurisdictions (specifically China) for drug substance supply.